ApoJ/Clusterin (CLU) is a heterodimeric protein localized in the nucleus, cytoplasm or secretory organelles and involved in cell survival and neoplastic transformation. Its function in human cancer is still highly controversial. In this study, we examined the prostate of mice in which CLU has been genetically inactivated. Surprisingly, we observed transformation of the prostate epithelium in the majority of CLU knockout mice. Either PIN (prostate intraepithelial neoplasia) or differentiated carcinoma was observed in 100 and 87% of mice with homozygous or heterozygous deletion of CLU, respectively. Crossing CLU knockout with TRAMP (prostate cancer prone) mice results in a strong enhancement of metastatic spread. Finally, CLU depletion causes tumourigenesis in female TRAMP mice, which are normally cancer free. Mechanistically, deletion of CLU induces activation of nuclear factor-kB, a potentially oncogenic transcription factor important for the proliferation and survival of prostate cells.
Introduction
ApoJ/Clusterin (CLU) is an enigmatic molecule, which was identified as an androgen-repressed gene in the prostate (Fritz et al., 1983; Bettuzzi et al., 1989) . The role of CLU in tumourigenesis is very controversial with evidence that CLU expression is increased or decreased in different cancer models (Shannan et al., 2006) . For example, some groups showed that CLU expression is increased in advanced stages of prostate cancer (Miyake et al., 2006) and that suppression of CLU expression sensitizes prostate cancer cells to chemotherapeutic drugs killing (Miyake et al., 2000; July et al., 2002; Trougakos and Gonos, 2002; Gleave and Miyake, 2005; Zhang et al., 2005) . Further evidence that CLU might be oncogenic is that it can bind to and inactivate BAX, inhibiting druginduced apoptosis, and cooperate with c-MYC in transforming mammalian cells (Zhang et al., 2005) . A tumourigenic effect of CLU in other types of epithelial cancer, like hepatocellular carcinoma, has been observed (Lau et al., 2006) . In contrast with the hypothesis that CLU is a prostate oncogene, we and others have observed that CLU is down-regulated during human prostate cancer progression Rauhala et al., 2008) . Moreover, we also found that CLU expression is down-regulated during prostate cancer progression in the TRAMP mouse model . When overexpressed, CLU causes growth inhibition and death of prostate cell lines, as a consequence of nuclear accumulation (Caccamo et al., 2003 (Caccamo et al., , 2005 Chen et al., 2004) . One of the possible explanations for the contrasting biological effects of CLU in different settings is that it can shuttle between the outside and inside the cell. One could speculate that accumulation in one of these cellular compartments leads to different biological outcomes. Indeed, nuclear CLU promotes apoptosis, whereas localization in the mitochondria or in the extracellular spaces promotes cell survival (Jones and Jomary, 2002; Zhang et al., 2005; Shannan et al., 2006; Nizard et al., 2007) . To define the role of CLU in prostate tumourigenesis in vivo, we crossed CLU knockout (CluKo) with TRAMP mice. The TRAMP model of prostate carcinogenesis was developed as an important tool for understanding the progression of prostate cancer (Greenberg et al., 1995) . TRAMP mice display in situ and invasive carcinoma of the prostate, mimicking the whole spectrum of human prostate cancer progression from prostate intraepithelial neoplasia (PIN) (Greenberg et al., 1995) to androgen-independent disease (Kaplan-Lefko et al., 2003) . TRAMP mice express the SV40 T/t antigen under the control of the prostate-specific, androgendependent minimal rat probasin promoter. Development of prostate cancer in TRAMP mice is thus SV40 driven and age related. CluKo mice manifest no overt defects, despite being more prone to cardiac autoimmunity (McLaughlin et al., 2000) . CluKo are also more susceptible than normal mice to chemically induced skin tumourigenesis, suggesting that CLU might be a negative modulator of epithelial cell transformation (ThomasTikhonenko et al., 2004) . In this study we found that CLU expression is critically required to suppress prostate cancer development.
Results
Oncomine is a publicly available database that has a large collection of gene expression experiments on human cancer (Rhodes et al., 2004) . We searched the database to understand whether CLU is up-or downregulated in prostate cancer. After setting a stringent P-value threshold of 0.0001, we observed that in 15 independent studies the expression of CLU was significantly down-regulated and inversely proportional to the grade and/or metastatic stage of prostate cancer (the results of 12 studies are shown in Figure 1 ; to visualize the complete set of experiments follow the link www.oncomine.org). Furthermore, the Oncomine analysis also suggests that CLU expression is inversely proportional to the Gleason score, an index of aggressive behaviour of human prostate cancer (Supplementary Figure 1 ).
CluKo mice manifest no overt defects, despite being more prone to cardiac autoimmunity (McLaughlin et al., 2000) . CluKo are also more susceptible than normal mice to chemically induced skin tumourigenesis, suggesting that CLU might be a negative modulator of epithelial cell transformation (Thomas-Tikhonenko et al., 2004) . To investigate whether genetic inactivation of CLU causes phenotypic alterations in the prostate epithelium, we inspected the prostate of several CluKo mice backcrossed to the 57BL6 strain. We first verified that CLU protein expression levels were decreased or absent in mice with one or zero copies of CLU (Supplementary Figure 2a) . We observed early and advanced intraepithelial neoplasia in five out of eight CluKo( þ /À) and six out of nine CluKo(À/À) at 40 weeks of age. Well-differentiated prostate cancer was found in two out of eight CluKo( þ /À) and three out of nine CluKo(À/À) (Table 1; Figure 2 ). Wild-type siblings did not show any cancer lesions. High expression of the proliferation marker Ki67 was detected in the normal, non-transformed portion of prostatic tissue of homoand heterozygous CluKo mice (Figure 3a , upper panels). Few stained nuclei were detected in the prostate of wildtype controls (Figure 3a , upper panels). Quantification of Ki67 staining in the normal prostatic tissue of CluKo mice showed a higher proliferation index compared to wild-type controls (Figure 3, panel b) .
Nuclear factor (NF)-kB has a pivotal role in mammalian prostate cancer, being required for prostate cancer cell proliferation and survival (Shukla et al., 2004 (Shukla et al., , 2005 Suh and Rabson, 2004) . Increased NF-kB activity in the prostate of CluKo mice could explain their increased susceptibility to develop spontaneous prostate carcinomas. Indeed, we observed that p65 NFkB staining was much more intense in the normal Clusterin is a suppressor of prostate cancer S Bettuzzi et al portion of the prostate or in low-grade PIN lesions of CLU-deleted mice compared to wild-type controls ( Figure 3a , bottom panels). To corroborate the hypothesis that endogenous CLU is involved in the control of NF-kB activity in mouse prostate cells, we transfected a CLU siRNA into TRAMP C2 cells along with a luciferase reporter vector containing NF-kB binding sites. TRAMP C2 cells express low levels of CLU because the gene is silenced by epigenetic mechanisms (Rauhala et al., 2008) . Still, knockdown of residual CLU expression caused a detectable increase of luciferase transcription, which was inhibited by the NF-kB inhibitor BAY, confirming the hypothesis that CLU is an inhibitor of NF-kB activity in prostate cells (Supplementary Figure 3) . To further define the role of CLU in prostate tumourigenesis in vivo, we crossed CluKo with prostate-cancer-prone TRAMP mice (Greenberg et al., 1995) . As expected, expression of CLU was reduced or absent in TRAMP mice with partial or total deletion of CLU (Supplementary Figure 2b) . Tumour spreading and homing were enhanced in TRAMP mice with deletion of CLU and metastases occurred earlier and in ectopic sites (Figure 4 , panels a and b; Table 1 ). Survival at 28 weeks of age (about 200 days) was 100, 83 and 70% in TRAMP, TRAMP/CluKo(À/ þ ) and TRAMP/CluKo(À/À), respectively (Figure 4 , panel c). After 200 days, the survival curves started to overlap. This is not surprising taking into consideration that in advanced prostate carcinoma CLU is down-regulated by epigenetic mechanisms Rauhala et al., 2008) . Ki67 staining was mainly detected in prostate cancer lesions in TRAMP mice. In contrast, diffuse Ki67 staining was detected in untransformed portions of the prostate of TRAMP/CluKo mice ( Figure 5 ). It was possible to observe nests of Ki67-positive cells arising from the basal cell layer, displacing the normal looking, fully differentiated luminal cells, which are negative for Ki67 ( Figure 5, panel g ).
As reported previously (Shukla et al., 2005) , NF-kB was overexpressed in the PIN or cancer lesions of TRAMP mice. Untransformed, prostatic tissue was essentially negative for NF-kB staining, whereas a clear NF-kB staining was detected in adjacent cancerous lesions (Supplementary Figure 4 , panels A, B, C and D). An even stronger NF-kB staining was detected in the neoplastic lesions of TRAMP/CluKo(À/À) mice (Supplementary Figure 4 panels E, F, G and H). Transformed epithelial cells positive for the SV40 transgene were also positive for Ki67 and NF-kB (Supplementary Figure 5) . Finally, an important observation is that 8% of TRAMP/CluKo(À/À) females (5 mice out of 60) had tumours, mostly localized to thyroid and uterus, but also to lymph nodes and lungs (Supplementary Figure 6) . Tumourigenesis in female TRAMP mice has been never reported and we found not a single tumour in TRAMP female mice with wild-type CLU alleles. Tumourigenesis most likely results from leakage of SV40 antigen expression due to minimal probasin promoter activity in female mice.
To assess whether CLU affects the growth and regulates key survival molecules of human prostate 
Afterwards the difference becomes non-significant and the curves start to merge. cells, we stably transfected a CLU, or a control, expression vector in the immortalized human prostate cell line PNT1a ( Figure 6 , panel a). IKBa was increased and NF-kB activity decreased in PNT1a cells transfected with exogenous CLU (Figure 6, panel b) . This is in line with our previous study where we observed proteasomal-induced degradation of IKB, and increased NF-kB activity, in mouse embryonic fibroblasts isolated from CluKo mice (Santilli et al., 2003) . Western blot analysis and confocal microscopy confirmed that CLU overexpression caused cytoplasmic accumulation of p65 ( Figure 6 , panels b and d). Notably, key pro-survival/ proliferation NF-kB target genes, such as phospho AKT, cyclin D1 and BCL2, were down-regulated in the presence of exogenous CLU. In contrast, expression of the growth suppressor p21 was increased and a robust slowdown of the cell cycle was noted in CLUtransfected PNT1a cells (Figure 6 , panels b and c). 
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To verify whether CLU levels correlate with the expression of NF-kB target genes in human prostate cancer, we carried out an in silico analysis using the Genesapiens database (http://ist.genesapiens.org/). This database allows the comparison of the relative expression levels of genes of interest in a collection of normal Clusterin is a suppressor of prostate cancer S Bettuzzi et al or cancer tissues. Assessment of the expression levels of CLU and the NF-kB target genes c-IAP1 and PSA, both important markers of prostate cancer (Wang et al., 1998; Chen and Sawyers, 2002; Nomura et al., 2005) , was monitored in 349 prostate adenocarcinomas. Interestingly, expression of CLU and NF-kB target genes was inversely correlated, further corroborating the hypothesis that loss of CLU expression in human prostate cancer results in higher NF-kB activity and expression of NF-kB target genes ( Figure 7 ).
Discussion
In this study we have addressed a question that has been puzzling researchers for a long time; is CLU a positive or negative modulator of mammalian tumourigenesis?
The observations reported here suggest that CLU is a negative modulator of prostate cancer and a putative haploinsufficient tumour suppressor gene. In agreement with this hypothesis, we have recently observed that deletion of just one allele of CLU promotes the development of MYCN-induced neuroblastomas in mice (Chayka et al., 2009) . Further validation of the theory that CLU is a tumour suppressor results from the frequent observation of CpG island methylation or histone deacetylation in the proximity of the CLU gene in different cancers (Nuutinen et al., 2005; Hellebrekers et al., 2007; Rauhala et al., 2008) . How could we reconcile the data shown in this report with previous findings suggesting that CLU is a pro-survival oncogene? The answer to this important question probably rests in the fact that cancer often exploits cellular genes, including tumour suppressor genes, to its own purposes. For example, it was recently shown that pRb is amplified and has a promoting role in colon cancer by suppressing E2F1 and enhancing cell survival by activating the Wnt pathway (Morris et al., 2008) . Along this line, the tumour suppressor protein PML, in the context of chronic myelogenic leukaemia, can behave like a tumour-promoting factor because it is required for the maintenance of a quiescent cancer-initiating population (Ito et al., 2008) . We hypothesize here that CLU could restrain tumourigenesis and metastatic spread by keeping in check NF-kB. Conversely, because a proapoptotic NF-kB signalling is involved in replication stress induced by chemotherapeutic drugs (Wu and Miyamoto, 2008) , highly malignant cells, including prostate cancer cells, could re-activate CLU expression to suppress NF-kB and survive. There are some limitations to this study that should be underlined. First, although loss of CLU induces the formation of hyperproliferative lesions or, in some instances, transformation of the prostate epithelium, we never observed progression into metastatic disease in the absence of an oncogenic stimulus, such as SV40 transgene expression. Indeed, CluKo mice live as long as control mice. Furthermore, although TRAMP mice have been widely used to model human metastatic prostate cancer, recent studies have revealed that there is a neuroendocrine component that complicates the interpretation of the results in this mouse model of human cancer (Chiaverotti et al., 2008) . Notwithstanding these limitations, the results of this study show that CLU is a suppressor of prostate tumourigenesis in mice and that CLU expression is largely lost in human prostate cancer patients. Our findings are not incompatible with the hypothesis that in subsets of prostate cancer patients reactivation of CLU expression will result in enhanced resistance to chemotherapeutic drug killing and cancer progression.
Materials and methods

Genetically modified mice
Male and female TRAMP mice heterozygous for the SV40 transgene were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and were maintained in a C57BL/6J background. CLU-deficient mice were backcrossed to the Clusterin is a suppressor of prostate cancer S Bettuzzi et al C57BL/6 strain and genotype was assessed by PCR as described (McLaughlin et al., 2000) . The animals were housed in a standard animal facility under controlled temperature with food and water provided ad libitum. Female TRAMP mice were mated with CLU-deficient homozygous (CluKoÀ/À) or heterozygous (CluKo þ /À) male mice. Necropsies of CluKo, TRAMP, heterozygous TRAMP/CluKo(À/ þ ) and homozygous TRAMP/CluKo (À/À) mice were conducted by an experienced pathologist. Prostates (all lobes) from killed animals were immediately frozen on dry ice and stored at À80 1C until used (for mRNA and protein analysis) or fixed in 10% (vol/vol) neutral-buffered formalin at 4 1C overnight and processed to paraffin using standard procedures for immunohistochemical analysis. Histopathological lesions were evaluated in a doubleblind manner by two independent pathologists. Animal care was approved by our institutional animal use and care committee.
Cell cultures TRAMP C2 cells were obtained from ATCC (Manassas, VA, USA). SV40-immortalized human prostate epithelial cell line PNT1A was established and characterized previously (Cussenot et al., 1991) . Cells were cultured in RPMI 1640 (Gibco Invitrogen s.r.l., Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and 1% L-glutamine. Cytofluorometric analysis of cell cycle was evaluated after staining the samples with propidium iodide (Sigma, St Louis, MO, USA). siRNAs siRNAs were purchased form Qiagen (Valencia, CA, USA) (Clu2: CAGAAGAAGUCUCUAAGGAUA) and Ambion (Austin, TX, USA) (negative control siRNA).
Luciferase assay
Cells were co-transfected with NFkB-Luc and pCMVb (Clontech, Mountain View, CA, USA). At 48 h after transfection, cell lysates were obtained by three freeze-and-thaw cycles in 250 mM Tris-HCl (pH 7.5), 15% glycerol and 10 mM dithiothreitol; 15% of the extract was used for the b-galactosidase assay and up to 30% for the luciferase assay. For the luciferase assay, samples were diluted to a 350 ml volume with LUC buffer (25 mM Glycilglycine (pH 7.8), 2 mM ATP, 10 mM MgSO 4 ) and incubated with 40 nm Luciferin (Sigma). Luciferase activity was measured in the luminometer LUMAT LB 9501 (Berthold, Oak Ridge, TN, USA). Luciferase activity was normalized to the b-galactosidase activity and to the protein concentration measured by Bradford assay.
Immunohistochemical analysis
Paraffin-embedded tissue sections (5 mm) were cut and mounted onto slides. Slides were hydrated in xylene, graded alcohol. Antigen retrieval was performed with sodium citrate (10 mM, pH 6) using microwave for 3 Â 5 min at 700 W. Endogenous peroxidase activity was quenched with 3% H 2 O 2 in H 2 O. Non-specific binding was blocked with swine serum dilute 1:10 in bovine serum albumin (BSA) 1% in phosphate-buffered saline (PBS). Immunostaining was performed using monoclonal antibodies anti-SV40T Ag (dilution 1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Ki67 (clone B56, dilution 1:10; BD Pharmingen, Franklin Lakes, NJ, USA), anti-NF-kB (clone F-6, dilution 1:50; Santa Cruz Biotechnology) diluted in BSA 1% in PBS and incubated 1 h at room temperature. From the secondary antibody to the chromogen reaction, the Universal LSAB þ System-HRP Kit (DakoCytomation, Glostrup, Denmark) was used. Counterstaining was performed with haematoxylin (Sigma Chemical Co, St Louis, MO, USA) and coverslips were mounted with Eukitt (O Kindler GmbH and Co, Freiburg, Germany). Counts were performed on high-power ( Â 40 objective) with a Zeiss (Thornwood, New York, NY, USA) Axioscop 40. Immunostaining was evaluated in a double-masked manner by two independent pathologists.
